Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use

Izumi Morita, Hiroyuki Oyama, Yui Kanda, Mayumi Yasuo, Aya Ito, Masahiro Toyota, Yoshinori Hayashi, Takeshi Yokoyama, Norihiro Kobayashi

Research output: Contribution to journalArticle

Abstract

Ketamine (KT) is a chiral anesthetic agent, (R)- and (S)-enantiomers of which differ in their pharmacological properties. KT has become one of the most commonly used illicit drugs in the world, thus, rapid and feasible on-site testing is required to crack down on the illicit use. Although immunochemical approach with specific antibodies is promising for this purpose, in practice anti-KT antibodies are difficult to obtain. We here disclose generation of monoclonal antibodies against KT. Mice were immunized with either (a) commercially- available or (b) in-house-prepared KT-albumin conjugates. Splenocytes from these mouse groups (a and b) were separately fused with P3/NS1/1-Ag4-1 myeloma cells. After standard screening and cloning, we established 5 hybridoma clones: 2 were derived from group-a mice [generating Ab-KT(a)#2 and #37] and 3 were from group-b mice [generating Ab-KT(b)#9, #13, and #45]. These antibodies exhibited practical performance in competitive enzyme-linked immunosorbent assay systems. When (±)-KT·hydrochloride (HCl) was used as the competitor, dose-response curves showed midpoint values of 30 and 70 ng/assay (a-series antibodies) and 2.0-3.0 ng/assay (b-series antibodies). Remarkably, the a-series antibodies were specific for (S)-KT·HCl, while the b-series antibodies were specific for (R)-KT·HCl. Ab-KT(a)#2 (Ka, 7.5×107 M-1) and Ab-KT(b)#45 (Ka, 7.7×108 M-1) exhibited the highest enantioselectivity for each group, and cross-reactivity with the (R)- and (S)-antipodes was 1.3 and 1.7%, respectively. The hybridomas established here are also valuable as a source of genetic information for the anti-KT antibodies, which is required for progressing to next-generation technologies using genetically engineered antibodies.

Original languageEnglish
Pages (from-to)123-131
Number of pages9
JournalBiological and Pharmaceutical Bulletin
Volume41
Issue number1
Publication statusPublished - Jan 1 2018

Fingerprint

Ketamine
Monoclonal Antibodies
Antibodies
Hybridomas
Anti-Idiotypic Antibodies
Street Drugs
Anesthetics
Organism Cloning
Albumins
Clone Cells
Enzyme-Linked Immunosorbent Assay
Pharmacology
Technology

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Morita, I., Oyama, H., Kanda, Y., Yasuo, M., Ito, A., Toyota, M., ... Kobayashi, N. (2018). Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use. Biological and Pharmaceutical Bulletin, 41(1), 123-131.

Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use. / Morita, Izumi; Oyama, Hiroyuki; Kanda, Yui; Yasuo, Mayumi; Ito, Aya; Toyota, Masahiro; Hayashi, Yoshinori; Yokoyama, Takeshi; Kobayashi, Norihiro.

In: Biological and Pharmaceutical Bulletin, Vol. 41, No. 1, 01.01.2018, p. 123-131.

Research output: Contribution to journalArticle

Morita, I, Oyama, H, Kanda, Y, Yasuo, M, Ito, A, Toyota, M, Hayashi, Y, Yokoyama, T & Kobayashi, N 2018, 'Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use', Biological and Pharmaceutical Bulletin, vol. 41, no. 1, pp. 123-131.
Morita I, Oyama H, Kanda Y, Yasuo M, Ito A, Toyota M et al. Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use. Biological and Pharmaceutical Bulletin. 2018 Jan 1;41(1):123-131.
Morita, Izumi ; Oyama, Hiroyuki ; Kanda, Yui ; Yasuo, Mayumi ; Ito, Aya ; Toyota, Masahiro ; Hayashi, Yoshinori ; Yokoyama, Takeshi ; Kobayashi, Norihiro. / Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use. In: Biological and Pharmaceutical Bulletin. 2018 ; Vol. 41, No. 1. pp. 123-131.
@article{48e759bf0c7241d29eed6c4c2a2def67,
title = "Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use",
abstract = "Ketamine (KT) is a chiral anesthetic agent, (R)- and (S)-enantiomers of which differ in their pharmacological properties. KT has become one of the most commonly used illicit drugs in the world, thus, rapid and feasible on-site testing is required to crack down on the illicit use. Although immunochemical approach with specific antibodies is promising for this purpose, in practice anti-KT antibodies are difficult to obtain. We here disclose generation of monoclonal antibodies against KT. Mice were immunized with either (a) commercially- available or (b) in-house-prepared KT-albumin conjugates. Splenocytes from these mouse groups (a and b) were separately fused with P3/NS1/1-Ag4-1 myeloma cells. After standard screening and cloning, we established 5 hybridoma clones: 2 were derived from group-a mice [generating Ab-KT(a)#2 and #37] and 3 were from group-b mice [generating Ab-KT(b)#9, #13, and #45]. These antibodies exhibited practical performance in competitive enzyme-linked immunosorbent assay systems. When (±)-KT·hydrochloride (HCl) was used as the competitor, dose-response curves showed midpoint values of 30 and 70 ng/assay (a-series antibodies) and 2.0-3.0 ng/assay (b-series antibodies). Remarkably, the a-series antibodies were specific for (S)-KT·HCl, while the b-series antibodies were specific for (R)-KT·HCl. Ab-KT(a)#2 (Ka, 7.5×107 M-1) and Ab-KT(b)#45 (Ka, 7.7×108 M-1) exhibited the highest enantioselectivity for each group, and cross-reactivity with the (R)- and (S)-antipodes was 1.3 and 1.7{\%}, respectively. The hybridomas established here are also valuable as a source of genetic information for the anti-KT antibodies, which is required for progressing to next-generation technologies using genetically engineered antibodies.",
author = "Izumi Morita and Hiroyuki Oyama and Yui Kanda and Mayumi Yasuo and Aya Ito and Masahiro Toyota and Yoshinori Hayashi and Takeshi Yokoyama and Norihiro Kobayashi",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "123--131",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Enantioselective monoclonal antibodies for detecting ketamine to crack down on illicit use

AU - Morita, Izumi

AU - Oyama, Hiroyuki

AU - Kanda, Yui

AU - Yasuo, Mayumi

AU - Ito, Aya

AU - Toyota, Masahiro

AU - Hayashi, Yoshinori

AU - Yokoyama, Takeshi

AU - Kobayashi, Norihiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ketamine (KT) is a chiral anesthetic agent, (R)- and (S)-enantiomers of which differ in their pharmacological properties. KT has become one of the most commonly used illicit drugs in the world, thus, rapid and feasible on-site testing is required to crack down on the illicit use. Although immunochemical approach with specific antibodies is promising for this purpose, in practice anti-KT antibodies are difficult to obtain. We here disclose generation of monoclonal antibodies against KT. Mice were immunized with either (a) commercially- available or (b) in-house-prepared KT-albumin conjugates. Splenocytes from these mouse groups (a and b) were separately fused with P3/NS1/1-Ag4-1 myeloma cells. After standard screening and cloning, we established 5 hybridoma clones: 2 were derived from group-a mice [generating Ab-KT(a)#2 and #37] and 3 were from group-b mice [generating Ab-KT(b)#9, #13, and #45]. These antibodies exhibited practical performance in competitive enzyme-linked immunosorbent assay systems. When (±)-KT·hydrochloride (HCl) was used as the competitor, dose-response curves showed midpoint values of 30 and 70 ng/assay (a-series antibodies) and 2.0-3.0 ng/assay (b-series antibodies). Remarkably, the a-series antibodies were specific for (S)-KT·HCl, while the b-series antibodies were specific for (R)-KT·HCl. Ab-KT(a)#2 (Ka, 7.5×107 M-1) and Ab-KT(b)#45 (Ka, 7.7×108 M-1) exhibited the highest enantioselectivity for each group, and cross-reactivity with the (R)- and (S)-antipodes was 1.3 and 1.7%, respectively. The hybridomas established here are also valuable as a source of genetic information for the anti-KT antibodies, which is required for progressing to next-generation technologies using genetically engineered antibodies.

AB - Ketamine (KT) is a chiral anesthetic agent, (R)- and (S)-enantiomers of which differ in their pharmacological properties. KT has become one of the most commonly used illicit drugs in the world, thus, rapid and feasible on-site testing is required to crack down on the illicit use. Although immunochemical approach with specific antibodies is promising for this purpose, in practice anti-KT antibodies are difficult to obtain. We here disclose generation of monoclonal antibodies against KT. Mice were immunized with either (a) commercially- available or (b) in-house-prepared KT-albumin conjugates. Splenocytes from these mouse groups (a and b) were separately fused with P3/NS1/1-Ag4-1 myeloma cells. After standard screening and cloning, we established 5 hybridoma clones: 2 were derived from group-a mice [generating Ab-KT(a)#2 and #37] and 3 were from group-b mice [generating Ab-KT(b)#9, #13, and #45]. These antibodies exhibited practical performance in competitive enzyme-linked immunosorbent assay systems. When (±)-KT·hydrochloride (HCl) was used as the competitor, dose-response curves showed midpoint values of 30 and 70 ng/assay (a-series antibodies) and 2.0-3.0 ng/assay (b-series antibodies). Remarkably, the a-series antibodies were specific for (S)-KT·HCl, while the b-series antibodies were specific for (R)-KT·HCl. Ab-KT(a)#2 (Ka, 7.5×107 M-1) and Ab-KT(b)#45 (Ka, 7.7×108 M-1) exhibited the highest enantioselectivity for each group, and cross-reactivity with the (R)- and (S)-antipodes was 1.3 and 1.7%, respectively. The hybridomas established here are also valuable as a source of genetic information for the anti-KT antibodies, which is required for progressing to next-generation technologies using genetically engineered antibodies.

UR - http://www.scopus.com/inward/record.url?scp=85040067921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040067921&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 123

EP - 131

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 1

ER -